Skip to search formSkip to main contentSkip to account menu

EB 1089

Known as: EB-1089, EB1089 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
1,25-Dihydroxyvitamin D3 and vitamin D3 analogues, such as EB 1089, potentiate the response to ionizing radiation in breast tumor… 
Highly Cited
2003
Highly Cited
2003
Treatment of cancer cells with 1,25-dihydroxyvitamin D3 [1,25(OH)(2)D(3)] or its analogs induces growth arrest and expression of… 
2003
2003
Although 1,25-dihydroxyvitamin D3 is a potent cell-differentiating agent, its use in cancer prevention or therapy is precluded… 
Highly Cited
2002
Highly Cited
2002
Objective  To determine the in vitro and in vivo effects of 1,25‐dihydroxyvitamin D 3 (calcitriol) and two newer less… 
2002
2002
Disruption of the gene for the cyclin dependent kinase inhibitor (CDKI) p27/kip1 results in pituitary corticotroph hyperplasia… 
2001
2001
Most breast cancer patients treated with anti-oestrogens will eventually develop resistance towards treatment. Therefore it is… 
1999
1999
Synthetic analogs of vitamin D induce apoptosis in cultured breast cancer cells and cause regression of experimentally-induced… 
Highly Cited
1997
Highly Cited
1997
PURPOSE: In this study, we investigated the effect of the vitamin D3analog, EB1089, on the growth of subcutaneous xenografts of… 
Highly Cited
1994
Highly Cited
1994
A basis for differentiation therapy of leukemias is provided by knowledge of agents which induce specific lineage maturation. All…